TÜBİTAK strengthens its ecosystem in the field of cancer research

Posted on by


While TÜBİTAK demonstrates its approach of “developing together and achieving together” against the difficulties within the scope of combating the new type of coronavirus (Kovid-19), it also carries out activities to strengthen its ecosystem in cancer research.

According to the information compiled by the AA correspondent, ecosystem actors with cancer research benefit from important programs of TUBITAK such as Industry Doctorate and National and International Leading Researchers.

Leading researchers contribute to cancer research, including cancer cell secretory proteins and nano-drugs. In addition, priority R&D and innovation issues presented to the ecosystem include health field priorities, including the development of micro / nano-carrier systems that can be directed to target areas in the body for cancer and autoimmune diseases.

With scientific and technological developments, studies are also being carried out on cancer treatments that may be much different in the coming years. New solutions for cancer are being developed with advances in cancer immunotherapy, disease-treating genome editing, precision medicine and digitalization in healthcare.

Diagnostic and therapeutic developments

TÜBİTAK Marmara Research Center (MAM) Genetic Engineering and Biotechnology Institute is also making new developments in cancer research.

Here, while identifying new therapeutic agents in lung cancer, 19 different peptides have been identified on the cell surface specific to lung cancer to develop a diagnostic system.

In another project, a genetically modified warrior T-cell-based therapy system is being developed. T cells, which are immune system cells, are genetically modified to make them susceptible to cancerous cells and conditioning them to destroy them.

Development is also being made in the project of developing targeted molecules suitable for the use of photodynamic therapy for both diagnosis and treatment of tumors. In this context, while 2 unique photodynamic therapy agents are being produced, a biosimilar drug project for cancer treatment is also carried out.

With “cancer” researches, which are determined as one of the mission areas within the scope of Ufuk Europe, it is aimed that patients with less cancer, cancer cases diagnosed earlier, are less affected and patients have a better quality of life during and after treatment. Turkey’s cancer research and is also a level that could contribute to this mission field.

TÜBİTAK, the relevant institution of the Ministry of Industry and Technology, also puts forward the “developing together and achieving together” approach against the difficulties in the fight against Kovid-19.